Rathbones Group PLC Acquires 1,796 Shares of Amgen Inc. $AMGN

Rathbones Group PLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 13.4% during the first quarter, Holdings Channel.com reports. The firm owned 15,165 shares of the medical research company’s stock after acquiring an additional 1,796 shares during the quarter. Rathbones Group PLC’s holdings in Amgen were worth $5,336,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in AMGN. Anfield Capital Management LLC grew its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its holdings in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the last quarter. Tower View Wealth Management LLC raised its holdings in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the last quarter. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC purchased a new stake in Amgen during the 4th quarter valued at $34,000. 76.50% of the stock is owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s second-quarter outlook calls for newer medicines to offset declines in parts of its legacy portfolio. Analysts are also assessing whether the company can exceed quarterly earnings expectations, which could support the shares if management delivers strong results or raises its outlook. Amgen Q2 preview: growth from newer drugs to offset legacy portfolio declines Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
• Positive Sentiment: An early-stage AMG 127 study signals Amgen’s expansion into type 2 diabetes, potentially opening another large market. However, the program remains preliminary and is not yet a near-term revenue driver. Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes
• Neutral Sentiment: Amgen obtained a license to Kaléo’s patented auto-injector technology. The deal could improve drug-device capabilities and patient convenience, but financial terms were undisclosed, limiting its immediate valuation impact. Kaléo Announces License Agreement with Amgen for Auto-Injector Technology
• Negative Sentiment: Amgen is investigating a data breach involving patient health information and proprietary company data. The scope and consequences remain unclear, but potential regulatory costs, litigation, remediation expenses and reputational damage are significant risks. This appears to be the principal near-term overhang ahead of earnings. Amgen contends with data breach, exposing patient information Amgen reveals material cyber breach with patient data stolen

Amgen Stock Down 1.6%

Shares of NASDAQ AMGN opened at $378.87 on Tuesday. The firm has a fifty day simple moving average of $357.39 and a two-hundred day simple moving average of $354.35. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $398.00. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $204.48 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 3.90 and a beta of 0.41.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is presently 70.15%.

Analysts Set New Price Targets

AMGN has been the topic of a number of analyst reports. UBS Group boosted their price objective on shares of Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Guggenheim upped their price target on Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $357.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.